Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on July 7, 2009
[Cancer Research, 10.1158/0008-5472.CAN-08-0289]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-0289v1
69/14/5811    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Satomaa, T.
Right arrow Articles by Saarinen, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Satomaa, T.
Right arrow Articles by Saarinen, J.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Analysis of the Human Cancer Glycome Identifies a Novel Group of Tumor-Associated N-Acetylglucosamine Glycan Antigens

Tero Satomaa 1*, Annamari Heiskanen 1, Iréne Leonardsson 4, Jonas Ångström 4, Anne Olonen 1, Maria Blomqvist 1, Noora Salovuori 1, Caj Haglund 2, Susann Teneberg 4, Jari Natunen 1, Olli Carpén 3, 5, and Juhani Saarinen 1

1Glykos Finland Ltd.; Departments of 2Surgery and 3Pathology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 4Department of Medical Biochemistry and Cell Biology, Göteborg University, Göteborg, Sweden; and 5Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland

* To whom correspondence should be addressed. E-mail: tero.satomaa{at}glykos.fi.


   Abstract

The cell surface is covered by a dense layer of protein- and lipid-linked glycans. Although it has been known that distinct glycan structures are associated with cancer, the whole spectrum of cancer-associated glycans has remained undiscovered. In the present study, we analyzed the protein-linked cancer glycome by matrix-assisted laser desorption/ionization time-of-flight mass spectrometric glycan profiling of cancer patient tissue samples. In lung cancer, we detected accumulation of a novel group of tumor-associated glycans. These protein-linked glycans carried abnormal nonreducing terminal {beta}-N-acetyl-D-glucosamine (GlcNAc) residues. A similar phenomenon was also detected in structural analyses of tumor-derived glycosphingolipids. This showed that glycan biosynthesis may dramatically change in cancer and that direct glycome analysis can detect the resulting marker glycans. Based on the structural knowledge, we further devised a covalent labeling technique for the detection of GlcNAc-expressing tumors with a specific transferase enzyme. In normal tissues, terminal GlcNAc antigens are capped by galactosylation. Similarly to common cancer-associated glycan antigens T, Tn, and sialyl-Tn, the newly discovered GlcNAc antigens result from incomplete glycosylation. In conclusion, the identified terminal GlcNAc glycans should be recognized as a novel class of tumor markers. [Cancer Res 2009;69(14):5811–9]

Key Words: cancer biomarkers, glycomics, mass spectrometry, glycosylation, N-acetylglucosamine







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.